Britain and America have hammered out a significant commercial pact that will ensure zero duties on British drug products entering the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This pledge ensures that tariffs on these crucial exports will remain at nothing for a period of the next three years.
This deal follows recent statements to significantly raise tariffs on branded pharmaceutical imports, with increases discussed as high as double the cost.
"This agreement with the UK reinforces the worldwide climate for new treatments and introduces much-needed balance to U.S.–U.K. medicine commerce," a statement declared.
Economic Importance
Drugs represent one of the UK's biggest exports to the America, which is easily the largest destination for large companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months to the end of September, the UK shipped drugs totaling over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that timeframe.
"This agreement protects employment, boosts capital expenditure and paves the way for the UK to emerge as a international leader for life sciences," the Business and Trade Secretary stated.
Key NHS Changes
The pact entails several key changes from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The percentage drug companies must pay back to the NHS to control costs will be restricted at 15%. Last year, repayments exceeded twenty percent.
Industry Background
This agreement takes place against a long-running row between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
The disagreement were intensified by arguments that American customers were paying several times more for the same drugs than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been announced toward American operations.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a percentage of its overall budget over the past decade.
